MedImmune, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
MedImmune, Inc. - overview
Location
Gaithersburg, MD, US
Primary Industry
Biotechnology
About
MedImmune, Inc. is a biopharmaceutical company dedicated to developing innovative therapies for serious infections and diseases, focusing primarily on respiratory and oncology treatments. MedImmune, Inc. specializes in the research and development of biopharmaceuticals.
In April 2007, the company was fully acquired by AstraZeneca for USD 15. 6 bn in a public-to-private transaction, enabling AstraZeneca to enhance its product portfolio. MedImmune operates from Gaithersburg, US, with a total of 1 deal recorded since its acquisition. AstraZeneca, through MedImmune, focuses on the discovery, development, and commercialization of innovative medicines targeting therapeutic areas such as oncology, respiratory diseases, and other serious conditions.
The product range includes prescription medications designed to improve patient outcomes and address significant medical needs across North America, Europe, and Asia. AstraZeneca generates revenue from the sales of pharmaceutical products via direct transactions with healthcare providers and institutions, including hospitals and pharmacies. The revenue is driven by flagship products that achieve substantial market shares, reflecting the competitive nature of the pharmaceutical industry through various pricing agreements with providers. Following its acquisition in April 2007, AstraZeneca plans to utilize the integration of MedImmune to expand and advance its product offerings.
This includes launching new products targeted at oncology and respiratory diseases. The company aims to enter new markets in Asia and Europe by 2025, leveraging the USD 15. 6 bn investment to support R&D initiatives and enhance its global market presence.
Current Investors
AstraZeneca
Primary Industry
Biotechnology
Sub Industries
Biotechnology
Website
www.medimmune.com
Total Amount Raised
Subscriber access only
MedImmune, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LP Direct, Public to Private | Completed | MedImmune, Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.